

Targinta presents positive preclinical data on the antibody-drug conjugate TARG9

The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), presents new preclinical data on the antibody-drug conjugate TARG9 at the 2nd Integrin-Targeted Drug Development Summit, Boston, on September 1, 2022 at 11 a.m. local time (17:00 CEST).

Targinta develops first-in-class tumor-targeting antibodies and antibody-drug conjugates (ADCs) against the unique and patent protected target integrin $\alpha 10\beta 1$. This cell adhesion receptor is highly expressed in some aggressive cancers such as glioblastoma but not at all in most normal tissues, making it an attractive target for ADCs.

TARG9 is a new generation ADC armed with a very potent cytotoxin. The concept builds on the fact that the tumor-targeting antibody delivers the cytotoxin very selectively to cancer cells, killing these but saving normal cells. The new data presented at the 2nd Integrin-Targeted Drug Development Summit in Boston includes the demonstration of strong and specific binding of TARG9 to integrin $\alpha 10\beta 1$. Further, TARG9 was found to internalize at a high rate and to induce cell death of integrin $\alpha 10\beta 1$ -expressing glioblastoma cells, even at low picomolar concentrations. And importantly, a single dose of TARG9 effectively inhibited tumor growth for more than 2 months in a preclinical glioblastoma model.

"The observed effects on tumor growth are truly impressive and gives strong support for the continued development of TARG9", says Per Norlén, CEO of Targinta.

For further information please contact:

Per Norlén, CEO Targinta AB

Email: per.norlen@targinta.se

Phone: +46 46 275 65 00

About Targinta

Targinta is a preclinical stage oncology biotech company, developing first-in-class tumor-targeting antibodies and antibody-drug conjugates (ADCs) for aggressive cancers based on the in-house discovery of the novel patent-protected cancer target integrin $\alpha 10\beta 1$. The pipeline includes TARG10, a function-blocking integrin $\alpha 10$ -antibody that is being developed to prevent metastasis, and TARG9, an integrin $\alpha 10$ -ADC that is armed with a powerful toxin that selectively kills tumor cells. Targinta is a wholly owned subsidiary of Xintela AB (publ) and is headquartered in Lund, Sweden. For more information, please visit www.targinta.se.

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin $\alpha 10\beta 1$ which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin $\alpha 10\beta 1$ (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

Attachments

[Targinta presents positive preclinical data on the antibody-drug conjugate TARG9](#)